Statistics for Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging

Total visits

views
Donanemab (LY3002813) Phase 1b Study in Alzheimer’s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging 122

Total visits per month

views
November 2024 0
December 2024 0
January 2025 1
February 2025 0
March 2025 27
April 2025 24
May 2025 3

File Visits

views
Lowe2021Donanemab-CCBY.pdf 1645
java.util.UUID:24aa5e61-003d-4683-a331-f7ed2c57c88b 484
java.util.UUID:be25737c-f30e-4f2b-a363-4fa37e978648 17
java.util.UUID:23adb036-2e0b-4de6-b563-88379ed83b8f 14

Top country views

views
United States 67
China 13
Spain 8
Australia 3
South Korea 3
United Kingdom 2
India 2
Argentina 1
Austria 1
Switzerland 1
Italy 1
Mexico 1

Top city views

views
Wilmington 42
Ann Arbor 5
Osaka 5
Shanghai 5
Tokyo 5
Cambridge 2
Germantown 2
Guargacho 2
Hangzhou 2
Hirosaki 2
Santiago de Compostela 2
Seoul 2
Stoke-on-Trent 2
Vienna 2
Acton 1
Ashburn 1
Baltimore 1
Beijing 1
Brisbane 1
Buenos Aires 1
Chennai 1
Chicago 1
Ciudad Madero 1
Fairfield 1
Franklin 1
Geneva 1
Houston 1
Hyderabad 1
Lake Mary 1
Los Angeles 1
Madrid 1
Melbourne 1
Mount Laurel 1
Nanjing 1
Nashville 1
Reston 1
San Cristóbal de La Laguna 1
San Miguel De Abona 1
Santa Cruz de Tenerife 1
Seodaemun-gu 1
Sydney 1
Trieste 1
Tustin 1
Washington 1